Hi Kmsmith,
Hope this helps.
Page 4, 6 & 11 of the May 2013 CEO Address AGM highlighted these three passages...
Page 4:
Eligible for regulatory advantages which come with Fast Track, Orphan Disease or Breakthrough designation that can significantly reduce the cost and time of bringing a new medicine to the market and provide additional clarity around the path to approval.
Page 6:
All of the indications that we've selected are expected to be eligible for fast track designation (which has already been issued for NNZ-2566 in TBI) and both Rett Syndrome and Fragile X Syndrome are potentially eligible for Orphan Drug Designation and possibly Pediatric Exclusivity. With strongly positive Phase 2 results, all would be expected for Breakthrough Therapy designation as well.
Page 11:
If the results of the Phase 2 trial are positive, we intend to request an end of Phase 2 meeting with the FDA to discuss requirements for a pivotal trial and registration under provisions of Fast Track and potentially Breakthrough Therapy designation. We are expecting that a pivotal trial would be the same size as the Phase 2 trial and could be completed within one year.
...............
As you are aware, Neuren have already been granted Fast Track for all indications (TBI, Rett and Fragile X Syndrome) as well as Orphan Drug Designation for Fragile X Syndrome. We are still waiting on Rett Syndrome Orphan Designation status.
Here are a few links on the above...
Breakthrough Therapy
http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/ucm341027.htm
Pivotal trial
If you look at the May 2012 AGM CEO Presentation it highlights this passage...
A second study in pediatric patients is planned for 2013. If the results of the Phase II trials are positive, we believe that a single pivotal trial in adolescents and adults and one in children would be required to submit an NDA for approval.
From Wikipedia, the free encyclopedia:
A pivotal trial can refer to a clinical trial or study intended to provide evidence for a drug marketing approval,[1] eg by the US FDA. Phase III trials are assumed to be pivotal so the phrase is often used for the rare pivotal phase II trials.
http://en.wikipedia.org/wiki/Pivotal_trial
http://www.lillytrials.com/docs/terminology.html#P
Here's an excellent video well worth watching...
Orphan Drugs - small market/big opportunity / Craig Kephart, President, Centric Health Resources
http://www.youtube.com/watch?v=1knkGIZrf0o
Regards,
Tony
- Forums
- ASX - By Stock
- NEU
- timeline question
timeline question, page-2
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$20.50 |
Change
0.400(1.99%) |
Mkt cap ! $2.579B |
Open | High | Low | Value | Volume |
$20.39 | $20.53 | $20.14 | $1.135M | 55.88K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 19 | $20.50 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.51 | 136 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 432 | 20.450 |
6 | 277 | 20.440 |
8 | 300 | 20.430 |
4 | 296 | 20.420 |
6 | 440 | 20.410 |
Price($) | Vol. | No. |
---|---|---|
20.470 | 37 | 2 |
20.480 | 485 | 3 |
20.490 | 300 | 5 |
20.500 | 1308 | 5 |
20.510 | 185 | 2 |
Last trade - 12.18pm 26/07/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |